Bone mineral content and bone mineral metabolism: changes after growth hormone treatment in juvenile chronic arthritis.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

To determine whether growth hormone (rhGH) affects bone mineral metabolism and bone mineral content (BMC, g/cm) in a therapeutic trial of recombinant growth hormone in growth retarded children with juvenile chronic arthritis (JCA) treated with steroid.

Who Took Part

The abstract describes 20 children taking part.

PubMed indexes the participants as young children, children and teenagers, both men and women.

How the Study Was Run

The design is described as randomized.

The children were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

Blood and urine samples were also obtained to measure indicators of disease activity, bone remodeling, and vitamin D and parathyroid hormone (PTH) status.

What Was Measured

PubMed files the paper under topics including Anti-Inflammatory Agents, Arthritis, Juvenile, Biomarkers, Bone Density, Bone and Bones, C-Reactive Protein and Calcium.

What This Means in Plain Language

The paper is a randomized study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and Vitamin D, K2, Magnesium and Zinc in 20 children.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2000 (The Journal of rheumatology), a journal based in Canada.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page and the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.